See What Is New In Dementia Research

Periodically I will search the web for newly publicized results of trials and will post them here. So far, no “magic bullets” have been discovered and many scientists are focusing on present healthy populations to see what lifestyle differences may benefit/protect the participants as they age.
It’s a multi-year study so we won’t be hearing what they have learned for a while!

Continue Reading →

LATE – A New Dementia Identified

When we talk about dementia today, most of the cases have been identified as Alzheimer’s disease and will occur after age 65 (called late-onset). On April 30th of this year in the issue of Brain (HealthDay News) co-author Dr. Peter Nelson of the University of Kentucky announced a new form of dementia. It affects people above the age of 80, and researchers think it has been around for a long time, probably misdiagnosed as Alzheimer’s disease. Researchers are calling this disease LATE which stands for limbic-predominant age-related TDP-43 encephalopathy.

Continue Reading →

Those Who Know They Have The APOE4 Gene For Alzheimers Are Running Out Of Time

On September 18th of this year the Alzheimer’s Prevention Initiative’s Generation Program (Novartis & Amgen with the Banner Alzheimer’s Institute) announced that they have stopped the BACE inhibitor drug study because of unexpected drops in memory and thinking of it’s study participants. When the group got word that this negative effect was happening, they looked at the data coming in from various study venues to verify that outcome. Once confirmed, they stopped the study cold.

Continue Reading →

40 Sites Around the US To Test A New Drug For Alzheimer’s Disease

This is a big deal. After so many years of failures in finding a drug to stop or even slow down the progression of Alzheimer’s disease (AD) most researchers have moved their focus to prevention of the disease before and signs or symptoms of dementia show up. This leaves those who have already been diagnosed feeling like they have been forgotten.

This study involves a precursor of the drug riluzole, a drug that has already been approved for ALS (amylotrophic lateral sclerosis, 1995). This precursor or “prodrug” as they call it is a related compound with lesser side effects that when taken is converted by the body into riluzole. It’s name is Troriluzole. The fact that it is converted by the body makes it a safer compound as well as more easily tolerated. For ALS, riluzole is an important find. Although it doesn’t cure the disease or quell the symptoms, it has been shown to increase survival time by at least a year and a half.

Continue Reading →

February 2018 Lewy-body Dementia Research Updates

Summarized from the Lewy-body Disease Association Website www.lbda.org Sumitomo Dainippon Pharma Co. Ltd. In 2014 it was discovered that motor…

Continue Reading →

Brain, Heal Thyself

It’s more likely to lose brain cells due to lack of use than overuse, this article explains. Mark Rosenzweig of U. of C. Berkeley and Michael Mersenich of U. of C. San Francisco and others found that with activity and exercise, that pathways in the brain actually changed. They found that the brain is “fluid” and can change by what we do. Both mental and physical exercise can lower the dementia risk. Vigorous daily exercise can lower the chances of getting dementia by 60% they say.

Continue Reading →

Brain Stimulation May Benefit Dementia Patients

University of Pennsylvania neuroscientists discovered that brain stimulation by a brain implanted “pacemaker” can increase memory function when given if the brain is in a “foggy” state. Psychologist Michael Kahana noted that the stimulation must be properly timed. If given when the brain is functioning well, it may decrease thinking skills.

Continue Reading →

LM11A-31 or C31

Summarized from “Alzheimer’s From A New Angle” by Alice Park, originally printed in Time Magazine.

A new drug called LM11A-31 or C31 as it’s known to its researcher Dr. Frank Longo from Stanford University School of Medicine is being tested right now in clinical trials. This drug is attacking the Alzheimer’s dilemma from a new angle. Instead of trying to dissolve the harmful proteins, amyloid plaques and tau protein tangles, he is using this nerve growth factor to bolster the brain neurons in order to help protect them from the damaging protein onslaught.

Continue Reading →